Internalized oAβ puncta colocalize with lysosomes in NG and HG mixed glia cultures. by Yung-Cheng Huang (3443450)

Subjects:

Confocal images of oAβ internalization by astrocytes in NG and HG mixed glia cultures. by Yung-Cheng Huang (3443450)

Subjects:

A hypoglycaemic <i>milieu</i> decreases NCS viability in a dose-dependent manner. by Shiva Mansouri (2838086)

FASN inhibitors result in decreased ΔΨm and increased superoxide production in melan-a cells. by Franco A. Rossato (588513)

FASN inhibitors result in decreased ΔΨm and increased superoxide production in melan-a cells. by Franco A. Rossato (588513)

Resveratrol decreases CYP17A1 and CYP21A2 protein expression. by Nesa Marti (3851059)

“…<p>A. Gene expression profiling by qRT-PCR was performed for CYP17, CYP21 and their cofactor POR in H295R cells grown under normal conditions (GM), starvation conditions (SM), metformin (Met) (1mM) treatment and under resveratrol (RSV) (5<u>μM)</u> treatment. …”

<i>SIRT6</i> Minor Allele Genotype Is Associated with >5-Year Decrease in Lifespan in an Aged Cohort by Mindi J. TenNapel (679433)

BMP type I receptor antagonists decrease Smad 1/5/8 activity in H1299 cells. by Elaine Langenfeld (402034)

Simultaneously inhibition <i>Nlu-miR-34</i> and <i>NlInR2</i> in SW strain induced the decrease of SW BPHs. by Xinhai Ye (6857771)

“…<p>(A) Antagomir-34 (with two different quantities) and ds<i>NlInR2</i> (0.84 ng) were injected into the third instar SW strain nymphs, showed that injection of antagomir-34 decreased the ratio of SW type BPH (Chi-square test, 40ng: χ² = 5.8, df = 1, <i>p</i> = 0.003; 60ng: χ² = 7.9, df = 1, <i>p</i> = 0.042). …”

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

CD5-2 decreases established CCM lesions in the hindbrain of <i>Ccm2</i>^<i>ECKO</i> mice and lesions in the retina of <i>Ccm2</i>^<i>ECKO</i> mice. by Jia Li (160557)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects: